Trifluridine/tipiracil hydrochloride

Drug Overview:

Trifluridine/tipiracil hydrochloride is an oral combination anticancer drug used for the treatment of metastatic colorectal cancer and metastatic gastric/gastroesophageal junction adenocarcinoma. It consists of a cytotoxic nucleoside analogue and an enzyme inhibitor that enhances its activity.

• Generic Name: Trifluridine and Tipiracil Hydrochloride
• US Brand Name: Lonsurf®
• Drug Class: Nucleoside Metabolic Inhibitor / Cytotoxic Chemotherapy Combination
• Route of Administration: Oral (tablet)
• FDA Approval Status: Approved for the treatment of:

1. Metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.
2. Metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and, if appropriate, HER2-targeted therapy.

Uncover facts on Trifluridine/tipiracil hydrochloride. Read our best, proven guide to learn safe uses, critical benefits, and top strategies.

What Is It and How Does It Work? (Mechanism of Action):

Trifluridine/tipiracil is a novel oral cytotoxic combination with a dual-component mechanism designed to inhibit cancer cell proliferation through DNA incorporation and thymidine salvage pathway blockade.

• Molecular Target: The active component, trifluridine (a nucleoside analogue), is incorporated into DNA. Tipiracil hydrochloride inhibits the enzyme thymidine phosphorylase.
• Cellular Impact: Trifluridine is phosphorylated intracellularly to its active trifluridine triphosphate form. This metabolite is incorporated into DNA during the S-phase of cell division, leading to dysfunctional DNA synthesis and strand breaks, which inhibit cell proliferation. However, trifluridine is rapidly degraded by thymidine phosphorylase in the gastrointestinal tract and liver. Tipiracil potently inhibits this enzyme, increasing the bioavailability and systemic exposure of trifluridine.
• Result: The combination results in sustained high levels of trifluridine, leading to its extensive incorporation into tumor cell DNA. This causes DNA dysfunction and instability, ultimately triggering cell death (apoptosis) in rapidly dividing cancer cells.
• Chemotherapy Agent: Trifluridine/tipiracil is an oral cytotoxic chemotherapy regimen. It represents a later-line treatment option with a mechanism distinct from other agents used in gastrointestinal cancers.

FDA Approved Clinical Indications:

• Oncological Uses:
  • Metastatic Colorectal Cancer (mCRC): Treatment of patients with mCRC who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF biological agent, and if RAS wild-type, an anti-EGFR therapy.
  • Metastatic Gastric Cancer: Treatment of patients with metastatic gastric or GEJ adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2-targeted therapy.
• Non-Oncological Uses:
  • There are currently no FDA-approved non-oncological indications.

Dosage and Administration Protocols:

The combination drug is administered orally according to a specific schedule to maximize therapeutic effect while managing its associated myelosuppression.

Renal and Hepatic Dose Adjustments

• Renal Impairment: Dose adjustments are generally necessary for patients with moderate renal impairment (Creatinine Clearance 30-50 mL/min, often starting at 20 mg/m²/dose BID. Use is not recommended for severe renal impairment CrCl <30 mL/min due to increased toxicity risk.
• Hepatic Impairment: Use is not recommended in patients with severe hepatic impairment due to limited clinical data and the potential for increased toxicity.

Clinical Efficacy and Research Results:

The approval of trifluridine/tipiracil was based on the global phase III RECOURSE (mCRC) and TAGS (gastric cancer) trials. Recent real-world data (2020-2025) support its use and explore novel combinations.

• Overall Survival in mCRC: In the RECOURSE trial, trifluridine/tipiracil demonstrated a statistically significant improvement in median overall survival compared to placebo (7.1 months vs. 5.3 months) in heavily pretreated mCRC, reducing the risk of death by 32%.
• Overall Survival in Gastric Cancer: In the TAGS trial, it improved median overall survival from 3.6 months with placebo to 5.7 months in previously treated metastatic gastric/GEJ cancer.
• Contemporary Research (2020-2025): Current investigations focus on:
  1. Moving to Earlier Lines of Therapy: Evaluating its combination with bevacizumab (anti-VEGF) in second-line mCRC, showing promising activity.
  2. Combination with Targeted Therapies: Studying combinations with other agents in molecularly selected populations.
  3. Real-World Effectiveness: Numerous studies confirm its clinical benefit and safety profile in routine practice align with clinical trial results.

Safety Profile and Side Effects:

Black Box Warning:

• Severe Myelosuppression: Can cause severe and life-threatening neutropenia, thrombocytopenia, and anemia.

Common Side Effects (>10%):

• Hematologic: Severe neutropenia, anemia, thrombocytopenia, and febrile neutropenia.
• Gastrointestinal: Nausea, vomiting, diarrhea, decreased appetite, abdominal pain.
• Constitutional: Fatigue, asthenia, pyrexia (fever).
• Other: Alopecia.

Management Strategies:

• Myelosuppression: Obtain complete blood counts prior to and on Day 15 of each cycle. Administer granulocyte colony-stimulating factor (G-CSF) as clinically indicated. Dose interruptions and reductions are mandatory for severe neutropenia or thrombocytopenia.
• Nausea/Vomiting: Prophylactic antiemetics are recommended. Manage breakthrough symptoms with additional medication.
• Diarrhea: Manage with antidiarrheal agents (e.g., loperamide) and ensure adequate hydration.
• Fatigue: Manage with scheduled rest, moderate activity, and nutritional support.

Serious Adverse Events

• Febrile Neutropenia / Serious Infection.
• Severe Hemorrhage due to thrombocytopenia.
• Embryo-Fetal Toxicity.

Research Areas:

Trifluridine/tipiracil is a focus of active clinical research aimed at expanding its utility. Current studies (2020-2025) are primarily investigating its combination with immunotherapy (e.g., pembrolizumab, atezolizumab) and targeted therapies (e.g., bevacizumab) in colorectal and gastric cancers. The goal is to enhance efficacy by combining its cytotoxic mechanism with immune activation or angiogenesis inhibition. There is no current research linking it directly to stem cell or regenerative medicine therapies.

Patient Management and Practical Recommendations:

Pre-treatment Tests:

• Complete Blood Count (CBC) with differential.
• Renal and Hepatic Function Tests.
• Pregnancy Test for women of childbearing potential.

Precautions During Treatment:

• Blood Count Monitoring: Strict adherence to the CBC monitoring schedule (pre-cycle and Day 15) is non-negotiable.
• Infection Precautions: Educate patients on signs of infection (fever, chills) and when to seek immediate medical attention.
• Administration: Take with food to reduce gastrointestinal upset.
• Drug Interactions: No strong inducers or inhibitors of CYP enzymes are known to interact, but caution is advised with all new medications.

Do’s and Don’ts:

• DO take the tablets twice daily after meals (breakfast and dinner) as prescribed.
• DO obtain your scheduled blood tests without delay.
• DO report fever (≥100.4°F / 38.0°C), chills, unusual bleeding/bruising, or severe diarrhea immediately.
• DON’T breastfeed while on this medication and for 1 day after the final dose.
• DON’T miss a scheduled blood test, even if you are feeling well.
• DON’T start any new medications, including over-the-counter drugs and herbal supplements, without consulting your oncology team.

Legal Disclaimer:

This guide is for informational purposes for patients and healthcare professionals. It summarizes the FDA-approved use and key risks of trifluridine/tipiracil and is not a substitute for professional medical advice. Treatment decisions are highly individualized. Always consult your qualified healthcare provider for advice on your specific condition and treatment.